A full-dose, clinician-guided option with titration tailored to your body
In the Flinders University study, of the 6954 women first prescribed GLP-1 receptor agonists during 2022, 90.5% did not have type 2 diabetes, suggesting that many were using the medication for weight loss
May 2026: Another 13 lawsuits have joined the multidistrict litigation alleging that Mounjaro and other GLP-1s may be associated with a risk of an eye stroke called NAION
The FDA has received reports of dosing errors associated with compounded GLP-1s, including patients accidentally taking too much or too little and experiencing complications such as fainting, dehydration and severe gastrointestinal symptoms
Start with a low dose
Options include increasing the semaglutide dose, switching to tirzepatide (which engages an additional receptor pathway), or adding a synergistic agent like naltrexone